IMDS.OB ...lots of volume for this stock

[52 windsor deluxe]

just bought some....chart looks like it trending up....stockcharts has some good indicators..what do you guys think?

[setravis]

Profile Get Profile for: 
 
Imaging Diagnostic Systems Inc.
6531 NW 18th Court
Plantation, FL 33313
Phone: 954-581-9800
Fax: 954-581-0555
Web Site: http://www.imds.com

DETAILS   
Index Membership: N/A
Sector: Healthcare
Industry: Medical Appliances & Equipment
Full Time Employees: 43


BUSINESS SUMMARY   
Imaging Diagnostic Systems, Inc., a development stage medical technology company, engages in the development and testing of a Computed Tomography Laser Breast Imaging System (CTLBIS) for detecting breast cancer. CTLBIS is an electro-mechanical scanner under microprocessor and computer control. The company was formed in 1993 and is headquartered in Plantation, Florida.

[setravis]

Press Release Source: Imaging Diagnostic Systems, Inc.


Imaging Diagnostic Systems CEO Interview Featured On WallSt.net
Friday December 30, 9:30 am ET


FORT LAUDERDALE, Fla., Dec. 30 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS - News) announces that Tim Hansen, CEO of Imaging Diagnostic Systems, was interviewed by WallSt.net, an online financial community website. The interview focused on answering the most frequently asked questions from investors and shareholders.
 
(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

The audio interview addressed the CT Laser Mammography Premarket Approval (PMA) submission process to the FDA, international sales, progress in research and development, and the company's recent participation at the Radiological Society of North America (RSNA).

The interview is featured on the WallSt.net website, http://www.wallst.net. A quick registration with the site is required to listen to the 14-minute interview. After registering, enter "IMDS" in the Audio Search box and select the 12/19/2005 interview.

The CTLM® system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000- 13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM® system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.

    Investor Relations:
     Rick Lutz
     404-261-1196
     [email protected]

--------------------------------------------------------------------------------
Source: Imaging Diagnostic Systems, Inc.

[setravis]

May have a set up to go for "Next Year"....
Possible FDA approval--laser mammography system.
IMDS has submitted and is processing with FDA for PMA approval for its CTLM patented breast laser imaging system, utilizing state of the art laser technology. Already approved in Europe, Asia, etc. and IMDS is selling these systems worldwide. Once FDA approval for US marketing, Wow....
Support @ 0.14...0.13
Resistance @ 0.17...0.18...0.19...0.20

Recent CandleStick Analysis
Very Bullish
Dec-30-2005 Bullish Engulfing 

Technicals
Stochastic is Bullish
MACD neutral
Close Above the 13-day EMA
Percentage Gainer

Last Price Quote is:
7.95%above 13-day EMA
-6.07%below 50-day EMA

[setravis]

Press Release Source: Imaging Diagnostic Systems, Inc.


Imaging Diagnostic Systems Selects M Squared Associates to Monitor Clinical Trials
Tuesday January 3, 9:30 am ET


FORT LAUDERDALE, Fla., Jan. 3 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS - News) announced today that M Squared Associates of Washington, DC, has been selected by IDSI to audit and monitor the company's clinical trials.


(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

"We are very pleased to have M Squared as our clinical trial monitor," stated Deborah O'Brien, Senior Vice President, IDSI. "It is highly important to us that we have exacting standards for following protocol and ensuring that the data is properly collected. With everything that M Squared has to offer, we look forward to working with them."

M Squared Associates will provide both expertise in clinical study management as well as experience with the FDA. The company's senior staff includes past executive managers from both Fortune 500 and early stage medical device companies, as well as past managers from the FDA Center for Devices and Radiological Health.

"We're very proud to be part of the team for the CTLM clinical study," said Marie Marlow, President and CEO of M Squared Associates. "We consider it a compliment when a company such as Imaging Diagnostic Systems chooses M Squared Associates as its contract research organization (CRO) partner. The CTLM system could benefit thousands of women with a potential diagnosis of breast cancer, so it's important to me both personally and professionally that this clinical study is well-run and supports a quick FDA approval."

M Squared Associates was founded in 2001 to specifically serve the clinical and regulatory needs of the medical device industry. The company specializes in bringing medical devices to market.

The CTLM® system is the first patented breast imaging system that utilizes state-of-the-art laser technology and patented algorithms to create 3-D cross-sectional images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000-13488 certification and FDA export certification for its CT Laser Breast Imaging system. The Company is seeking PreMarket Approval (PMA) from the Food and Drug Administration (FDA) for its CTLM® system to be used as an adjunct to mammography.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission.


    Investor Relations:
    Rick Lutz
    404-261-1196
    [email protected]
--------------------------------------------------------------------------------
Source: Imaging Diagnostic Systems, Inc.

[setravis]

Broke the downtrend line, nice volume the last 2 or 3 trading days.
Volume: 1,647,319......
Avg Volume (3m): 616,430

The website, www.imds.com, states that the company is preparing to resubmit its application for PMA to the FDA. When the PMA is submitted the FDA has 180 days to respond. IMHO  this stock will have a significant bounce when it actually resubmits the PMA and a big WOW, when and if it is approved. The CTLM concept is exciting and the women of the world are waiting for and hoping for an advance in breast cancer detection.

[setravis]

active in the pre-market
+11.76%

[cgill]

Imaging Diagnostic Systems' CT Laser Breast Imaging Scanner Enters US FDA Clinical Trials
Monday May 1, 11:34 am ET


FORT LAUDERDALE, Fla., May 1 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS - News) announced today that clinical trials of the CT Laser Mammography (CTLM®) system have commenced at a number of US university medical centers. IDSI will collect clinical data through a non- significant risk (NSR) device study.
ADVERTISEMENT
 




(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

"As previously reported, we will be scanning patients using the latest version of the CTLM system," commented Deborah O'Brien, Senior Vice President of Imaging Diagnostic Systems. "Following data collection and analysis, we intend to submit a Premarket Approval application to the FDA for the use of CTLM as an imaging adjunct to conventional diagnostic mammography. CTLM has the potential to fill an important role in improving the accuracy of current breast cancer detection methods and in improving patient management. We are partnering with prestigious institutions, using an experienced clinical study management firm, working with leading regulatory consultants, and using our best efforts to ensure successful clinical trials."

"We are also moving forward in our global commercialization efforts. We held our first International CTLM Users Meeting in April. Many of our international users have gained useful experience and collectively have scanned over 7,000 breasts. IDSI recently participated in the European Congress of Radiology, where several of our luminary partners presented clinical studies," O'Brien added.

The Company will continue to provide periodic updates of its progress on current initiatives, including the US PMA process, by way of shareholder letters, press releases, and other public filings. The locations of the clinical trials will not be disclosed so that the study members may participate without publicity or distraction.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company's clinical investigation is a non- significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM® system is the first patented breast imaging system that utilizes state-of-the- art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.


     Investor Relations:
     Rick Lutz
     404-261-1196
     [email protected]




--------------------------------------------------------------------------------
Source: Imaging Diagnostic Systems, Inc.

[investor2005dd]

This company was unable to get fda approval about 2 yrs ago. The stock price ran about 1.50 prior to fda decision. They will go for it again and when it happens it will be big. Check it out I think they have a great product!

Imaging Diagnostic Systems' CT Laser Breast Imaging Scanner Enters US FDA Clinical Trials
Monday May 1, 11:34 am ET


FORT LAUDERDALE, Fla., May 1 /PRNewswire-FirstCall/ -- Imaging Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS - News) announced today that clinical trials of the CT Laser Mammography (CTLM®) system have commenced at a number of US university medical centers. IDSI will collect clinical data through a non- significant risk (NSR) device study.
ADVERTISEMENT


(Logo: http://www.newscom.com/cgi-bin/prnh/20040412/IMDSLOGO )

"As previously reported, we will be scanning patients using the latest version of the CTLM system," commented Deborah O'Brien, Senior Vice President of Imaging Diagnostic Systems. "Following data collection and analysis, we intend to submit a Premarket Approval application to the FDA for the use of CTLM as an imaging adjunct to conventional diagnostic mammography. CTLM has the potential to fill an important role in improving the accuracy of current breast cancer detection methods and in improving patient management. We are partnering with prestigious institutions, using an experienced clinical study management firm, working with leading regulatory consultants, and using our best efforts to ensure successful clinical trials."

"We are also moving forward in our global commercialization efforts. We held our first International CTLM Users Meeting in April. Many of our international users have gained useful experience and collectively have scanned over 7,000 breasts. IDSI recently participated in the European Congress of Radiology, where several of our luminary partners presented clinical studies," O'Brien added.

The Company will continue to provide periodic updates of its progress on current initiatives, including the US PMA process, by way of shareholder letters, press releases, and other public filings. The locations of the clinical trials will not be disclosed so that the study members may participate without publicity or distraction.

Imaging Diagnostic Systems is seeking FDA Premarket Approval (PMA) for its Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The Company's PMA application will be submitted in its entirety at the completion of the data collection and review process. The FDA has determined that the Company's clinical investigation is a non- significant risk (NSR) investigational device study because it does not meet the definition of a significant risk (SR) device under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM® system is the first patented breast imaging system that utilizes state-of-the- art laser technology and patented algorithms to create 3-D images of the breast. It is a non-invasive, painless examination that does not expose the patient to radiation or require breast compression. Imaging Diagnostic Systems has received CE Marking, CMDCAS (Canada), Canadian License, China SFDA approval, UL listing, ISO 9001:2000, ISO 13485:2003 certification and FDA export certification for its CT Laser Mammography system.

Please visit Imaging Diagnostic Systems' website at: http://www.imds.com for additional information.

In conjunction with the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future anticipated projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates of future results and there can be no assurance that actual results will not materially differ from expectation. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filing with the Securities Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.


Investor Relations:
Rick Lutz
404-261-1196
lcgroup*mindspring.com

[setravis]

"IMDS.OB" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.         
All history on a stock pick in 1 thread is awesome.       

Thank You....and good luck with all your trades....make some $$$     


I will leave you Friday's closing chart........